<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00158704</url>
  </required_header>
  <id_info>
    <org_study_id>GS-00-480</org_study_id>
    <nct_id>NCT00158704</nct_id>
  </id_info>
  <brief_title>Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection.</brief_title>
  <official_title>An Open-Label, Continued Access Study of Adefovir Dipivoxil for Patients With Chronic HBV Infection Who Have Completed a Gilead-Sponsored Study of Adefovir Dipivoxil.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      Provide adefovir dipivoxil (Hepsera) 10 mg once daily to patients with chronic hepatitis B&#xD;
      virus (HBV) infection who have completed a Gilead-sponsored study of adefovir dipivoxil and&#xD;
      require continued access to adefovir dipivoxil.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to provide adefovir dipivoxil 10 mg once daily to patients&#xD;
      with chronic hepatitis B virus(HBV) infection who have completed a Gilead-sponsored study of&#xD;
      adefovir dipivoxil and require continued access to adefovir dipivoxil. The secondary&#xD;
      objective of this study is to evaluate the safety of chronic therapy with adefovir dipivoxil&#xD;
      10 mg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study stopped due to marketing approval by the FDA.&#xD;
  </why_stopped>
  <start_date>January 2002</start_date>
  <completion_date>January 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide adefovir dipivoxil (ADV) 10 mg once daily to patients with chronic hepatitis B virus (HBV) infection who have completed a Gilead-sponsored study and require continued access to ADV.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of chronic therapy with ADV 10 mg.</measure>
  </secondary_outcome>
  <enrollment>400</enrollment>
  <condition>Hepatitis B</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hepsera</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have completed one of the following Gilead-sponsored studies as indicated:&#xD;
             GS-96-412, GS-98-437, GS-98-438, GS-00-461 and GS-00-481. If the patient has&#xD;
             participated in another Gilead-sponsored study, the CRO or Sponsor's Medical Monitor&#xD;
             will evaluate for participation in this study on a case by case basis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any serious or active medical or psychiatric illness that would interfere with patient&#xD;
             treatment, assessment or compliance with the protocol or dosing requirements.&#xD;
&#xD;
          -  Currently receiving nephrotoxic drugs such as aminoglycosides (e.g. amikacin,&#xD;
             gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin), amphotericin&#xD;
             B, vancomycin, cidofovir, foscarnet, cisplatin, or pentamidine OR competitors of renal&#xD;
             excretion such as probenecid and sulfinpyrazone. These agents must be discontinued at&#xD;
             least 7 days prior to starting treatment with adefovir dipivoxil.&#xD;
&#xD;
          -  Currently receiving investigational agents with activity against hepatitis B virus.&#xD;
&#xD;
          -  Hypersensitivity to any of the components of the drug product.&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Inability to comply with study requirements.&#xD;
&#xD;
          -  Experienced a treatment limiting toxicity of adefovir dipivoxil that has not yet&#xD;
             resolved or resulted in permanent discontinuation of adefovir dipivoxil in the&#xD;
             previous study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://www.Gilead.com</url>
    <description>Website for Gilead</description>
  </link>
  <verification_date>April 2006</verification_date>
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>March 7, 2007</last_update_submitted>
  <last_update_submitted_qc>March 7, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2007</last_update_posted>
  <keyword>Chronic Hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

